Abstract
Report description
The Bigpharma Dealmaking Handbook 2007 provides an in-depth insight
into the dealmaking interests and activity of the worlds leading fifty
biopharma companies.
Using this report, dealmakers will effectively and efficiently target their
partnering activities to deliver the company' s business development objectives.
The initial chapters of this report provide an orientation of bigpharma' s
dealmaking and business activities. Chapter 1 provides an introduction to the
report, whilst chapter 2 lists the top 50 leading biopharma companies based on
2006 pharmaceutical revenues. Chapter 3 analyses the most active dealmakers in
2005 and 2006 in M&A and partnering deals announced, whilst chapter 4 analyzes
the top deals of 2005-6 according to reported deal size.
Chapter 5 provides a summary on best practice on how to submit an opportunity
to bigpharma, to ensure building of relationships and to obtain a prompt
assessment and response from the business development function of the
prospective partner. Chapter 6 lists forthcoming partnering events where
valuable face to face meetings with bigpharma provide a highly effective means
of obtaining interest in novel opportunities.
The main body of the report is provided in chapter 7 and 8. Firstly, a series
of matrices provide a cross reference for each bigpharma company versus
therapy area with respect to marketed and pipeline activity, partnering
interests, and partnering activity in the last two years. Secondly, in-depth
profiles of every bigpharma company provide everything required to assess the
suitability of a company as a prospective partner. This includes a company
overview, detailed analysis of the company' s marketed and pipeline disease
targets, partnering interests, partnering activity according to deal type,
phase of development, therapy area. Each profile also includes in-depth
contact information for individuals within the business development function.
In addition, each company profile provides a listing of deal contract
documents available in the public domain, each of which can be obtained from
CurrentPartnering, either individually or as part of a contract set. See each
company profile for further details.
Key benefits
Bigpharma Dealmaking Handbook 2007 provides the user with the following
key benefits:
- A comprehensive overview of the partnering activities and interests of the
leading fifty biopharma companies
- Identify prospective partner companies by analyzing their dealmaking
activity and interests
- Undertake initial due diligence to assess suitability of partner companies
- Make direct contact with over 1,300 named business development executives
- Identify over 1,000 actual contract agreements entered into by the company
and its partner companies
- Understand the key deal terms the company has agreed in previous deals
Report scope
Bigpharma Dealmaking Handbook 2007 is intended to provide the reader with an
in-depth understanding of the partnering activities and interests of the
leading fifty biopharma companies worldwide, enabling the effective assessment
and selection of partners of choice, based on the latest knowledge of a
company' s approach to partnering.
Bigpharma Dealmaking Handbook 2007 includes:
- The tools to enable effective and efficient partnering with bigpharma
- Detailed partnering activity and interests profiles for the leading fifty
bigpharma companies
- Direct contact information for over 1,300 bigpharma dealmakers
- Listing of over 1,000 contract documents between bigpharma and partner
companies
- The leading M&A and partnering deals by value 2005-6
- Most active M&A and partnering dealmakers 2005-6
- Guidelines on how to submit partnering opportunities to bigpharma
- The leading partnering resources and networking events
The Bigpharma Dealmaking Handbook 2007 provides a comprehensive profile
for each of the fifty bigpharma companies, including:
- Detailed company profile
- In-depth marketed and pipeline activity of each company
- Partnering interests statement and therapy focus
- Partnering activity for 2005-2006
- Activity by deal type
- Activity by phase of development
- Activity by therapeutic area
- List of recent partner companies
- Direct contact information for dealmakers
- General company and partnering contact information
- List of contract documents available* to allow analysis of bigpharma deal
terms
Number of pages: The report is comprised of 438 pages.
Table of Contents
Executive Summary
Chapter 1 - Introduction
Chapter 2 - Bigpharma - The Top 50
Chapter 3 - Most active bigpharma dealmakers
- 3.1 Bigpharma M&A activity
- 3.2 Bigpharma partnering
Chapter 4 - Top bigpharma deals - 2000-6
- 4.1 Bigpharma M&A
- 4.2 Bigpharma partnering
Chapter 5 - Submitting Opportunities to Bigpharma
- 5.1 How to submit an opportunity
- 5.2 Opportunity submission template
- 5.3 Sending emails
- 5.4 Face to face at partnering events
- 5.5 Online submission forms
Chapter 6 - Forthcoming bigpharma partnering events
Chapter 7 - Bigpharma company - therapy locator
- 7.1 How to use the therapy matrix tables
- 7.2 Therapeutic area definitions
- 7.3 Bigpharma - Therapeutic target matrix - marketed and pipeline compounds
- 7.5 Bigpharma - Therapeutic target matrix - expressed partnering interests
- 7.6 Bigpharma - Therapeutic target matrix - recent deals - 2005-2006
Chapter 8 - Bigpharma Company Profiles
- 8.1 How to use company profiles
- 8.2 Field definitions
- 8.3 Company profiles
- Each profile includes:
- Company contact details
- Subsidiary companies
- Primary therapy areas
- Business development contacts
- Company description
- Marketed therapeutic indications
- Pipeline (phase I-III) therapeutic indications
- Partnering interests
- Partnering interests - therapeutic indications
- Partnering frequency per annum - 2000-2006
- Current partner companies (2005-6)
- Recent deals 2005-2006
- By deal type
- By stage of development
- By therapy area
- Contract documents available
Company profiles:
- Abbott
- Actavis
- Akzo Nobel
- Allergan
- Altana
- Amgen
- Astellas
- AstraZeneca
- Baxter International
- Bayer
- Bayer Schering Pharma AG
- Biogen Idec
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Cephalon
- Chugai
- CSL
- Dainippon Sumitomo
- Eisai
- Eli Lilly
- Forest Laboratories
- Genentech
- Genzyme
- Gilead Sciences
- GlaxoSmithKline
- Johnson & Johnson
- King
- Lundbeck
- Menarini
- Merck & Co
- Merck - Serono KGaA
- Mitsubishi
- Novartis AG
- Novo Nordisk
- Nycomed Pharma
- Otsuka
- Pfizer
- Procter & Gamble
- Roche
- Sanofi-Aventis
- Schering Plough
- Serono
- Shionogi Seiyaku
- Shire
- Solvay
- Takeda
- Tanabe Seiyaku
- TAP Pharmaceuticals
- Teva
- UCB
- Watson
- Wyeth
Chapter 9 - Resources
Appendices
- Appendix 1 - Example contract document
About CurrentPartnering
Recent titles from CurrentPartnering
Order form - Reports
Order form - Company Dealmaking Profiles
Order Form - Company Contract Sets
Order Form - contract sets
Order Form - contract documents
Order Form - Report update subscription
Figures in report
- Figure 1: Bigpharma - top 50 by pharma revenues 2006
- Figure 2: Additional bigpharma companies profiled in report
- Figure 3: Leading Bigpharma M&A companies, 2005-6
- Figure 4: Leading Bigpharma partnering companies, 2005-6
- Figure 5: Leading M&A deals by value, 2005-6
- Figure 6: Leading partnering deals by value, 2005-6
- Figure 7: Typical partnering opportunity submission template
- Figure 8: Partnering events 2007-8
- Figure 9: Therapeutic area definitions
- Figure 10: Therapeutic target matrix - marketed and pipeline compounds
- Figure 11: Therapeutic target matrix - expressed partnering interests
- Figure 12: Therapeutic target matrix - recent deals 2005-6
- Figure 13: Company profile template and definitions used in report
- Figure 14: Online partnering resources
- Figure 15: Development and license agreement between Boehringer Ingelheim
and Inspire Pharmaceuticals, February 2006
|
